Latest Impairment News

Clean Seas Seafood Limited has entered a binding scheme of arrangement with Yumbah Aquaculture, offering shareholders a 52% premium cash exit or a speculative scrip alternative. The Independent Board Committee recommends approval, with a shareholder meeting set for June 23.

Marimaca Copper Corp reported a net loss of $2.25 million for Q1 2025, maintaining solid liquidity while managing risks tied to a significant receivable under liquidation proceedings.

Paladin Energy reports a 17% rise in quarterly uranium production and US$61 million in revenue, while recognizing a US$19.9 million inventory impairment. The company maintains strong liquidity and advances key projects in Namibia and Canada.

TasFoods reported a $10.7 million net loss for FY2024, challenged by an oversupplied poultry market and a significant asset impairment. The company is pivoting towards growth in pet treats and dairy exports to stabilize its future.

Dyno Nobel Limited reported a mixed half-year performance with a modest dip in revenues but a significant rise in net profit from continuing operations. The company is accelerating its transformation through major asset sales and a recommencement of its substantial share buyback program.

Macquarie Group Limited reported a 5% increase in net profit to A$3.715 billion for FY2025, driven by growth in asset management and banking segments alongside a robust capital and liquidity position.

Macquarie Group reported a 5% rise in full-year net profit to A$3.715 billion for FY25, driven by growth across its diversified businesses and a solid capital position. The group’s assets under management reached A$941 billion, supported by strong home loan and deposit growth.

Nyrada’s experimental drug NYR-BI03 shows promising cardioprotective and anti-arrhythmic effects in animal models, reinforcing its potential as a treatment for acute myocardial infarction.

LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.

Orica Limited reported a robust first half FY2025 with a 40% rise in NPAT pre-significant items and strong cash flow, underpinned by demand for premium blasting and digital solutions. The company also announced a $400 million share buy-back and a 32% higher interim dividend.

Orica Limited reported a 7.7% increase in revenue to $3.94 billion for the half year ended March 2025, but posted a net loss of $89 million due to significant impairment and restructuring charges. Excluding these items, net profit rose 40% to $250.8 million, with the board declaring a higher interim dividend.

ANZ Group Holdings Limited posted a 7% increase in statutory profit to AUD 3.642 billion for the half year ended 31 March 2025, with stable cash profit and an 83 cent interim dividend. The full integration of Suncorp Bank underpinned lending and deposit growth, while credit impairments eased.